Equities

Larimar Therapeutics Inc

Larimar Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.04
  • Today's Change-0.25 / -2.69%
  • Shares traded581.90k
  • 1 Year change+268.98%
  • Beta0.9595
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Larimar Therapeutics Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 33.35m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 33.46m for operations while cash generated from financing totalled 30.00k.
Cash flow per share-1.14
Price/Cash flow per share--
Book value per share3.11
Tangible book value per share3.11
More ▼

Balance sheet in USDView more

Larimar Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio13.10
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.